BC
BBIO icon

BIT Capital’s BridgeBio Pharma BBIO Stock Holding History

BIT Capital’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-1,056
Closed -$54.8K – 112
2025
Q3 		$54.8K Sell
1,056
-16,504
-94% -$805K ﹤0.01% 103
2025
Q2 		$758K Sell
17,560
-540,086
-97% -$19.6M 0.04% 61
2025
Q1 		$19.3M Buy
557,646
+282,731
+103% +$9.53M 1.65% 19
2024
Q4 		$7.54M Buy
274,915
+52,494
+24% +$1.36M 0.6% 26
2024
Q3 		$5.66M Buy
222,421
+93,208
+72% +$2.45M 0.53% 35
2024
Q2 		$3.27M Sell
129,213
-9,484
-7% -$259K 0.26% 46
2024
Q1 		$4.29M Buy
138,697
+65,207
+89% +$2.22M 0.32% 50
2023
Q4 		$2.97M Buy
73,490
+67,133
+1,056% +$2.02M 0.29% 46
2023
Q3 		$168K Buy
+6,357
New +$180K 0.02% 90

Other funds holding BBIO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BIT Capital's BBIO Position: Q4 2025 in Review

BIT Capital sold out of BridgeBio Pharma (BBIO) in Q4 2025, closing a stake of 1,056 shares — an estimated $54.8K sold.

BIT Capital first reported a position in BBIO in Q3 2023 and held it in 9 quarters. The position peaked at $19.3M in Q1 2025. 433 funds tracked by Wall St. Rank hold BBIO as of Q4 2025.

  • BIT Capital reported no remaining BridgeBio Pharma position as of Q4 2025 after selling out during the quarter.
  • BIT Capital sold 1,056 BridgeBio Pharma shares in Q4 2025, an estimated $54.8K.
  • BIT Capital first reported a position in BridgeBio Pharma in Q3 2023 and held it in 9 quarters.
  • BIT Capital's BridgeBio Pharma position peaked at $19.3M in Q1 2025.
  • 433 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q4 2025.

Based on BIT Capital's 13F filing for Q4 2025, filed 11 Feb 2026.